Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine

• Published in: Gan to kagaku ryoho Vol. 33; no. 13; p. 2089
• Main Authors: Honda, Kazuo, Fukuhara, Toshiyuki, Kojima, Yoh, Tanaka, Hitoshi, Kushihata, Fumiki, Kobayashi, Nobuaki
• Format: Journal Article
• Language: Japanese
• Published: Japan 01-12-2006
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - secondary; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Capecitabine; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Drug Administration Schedule; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Humans; Infusions, Intravenous; Leukopenia - chemically induced; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Taxoids - administration & dosage; Vascular Neoplasms - drug therapy; Vascular Neoplasms - pathology
• ISSN: 0385-0684

Two cases of advanced pancreas cancer were treated with GTX. One cycle was 3 weeks, capecitabine (1,000 mg/m(2)/day) was administered from day 1 to 14, and GEM 750 mg/m(2) and DOC 30 mg/m(2) were drip-infused on day 4 and 11. A 62-year-old man with pancreas head cancer and 2 liver metastases was treated with GEM 1,000 mg/m(2)/week at weeks 1, 2, and 3, and drug-free week 4 for 3 cycles, but was PD. After 3 cycles of GTX, the liver metastases decreased in size, and thereafter tumor markers became lowest after 7 cycles. The patient was shifted to another regimen after 14 cycles for 9 months of GTX. A 75-year-old man with pancreas head cancer and vascular invasion has been treated with GTX. As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles. The tumor reduced in size and tumor markers decreased. GTX is suitable for outpatient chemotherapy with mild adverse effects.